203 related articles for article (PubMed ID: 36380143)
1. Preclinical efficacy of azacitidine and venetoclax for infant KMT2A-rearranged acute lymphoblastic leukemia reveals a new therapeutic strategy.
Cheung LC; Aya-Bonilla C; Cruickshank MN; Chiu SK; Kuek V; Anderson D; Chua GA; Singh S; Oommen J; Ferrari E; Hughes AM; Ford J; Kunold E; Hesselman MC; Post F; Faulk KE; Breese EH; Guest EM; Brown PA; Loh ML; Lock RB; Kees UR; Jafari R; Malinge S; Kotecha RS
Leukemia; 2023 Jan; 37(1):61-71. PubMed ID: 36380143
[TBL] [Abstract][Full Text] [Related]
2. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
Schafer E; Irizarry R; Negi S; McIntyre E; Small D; Figueroa ME; Melnick A; Brown P
Blood; 2010 Jun; 115(23):4798-809. PubMed ID: 20215641
[TBL] [Abstract][Full Text] [Related]
5. Combined BCL-2 and PI3K/AKT Pathway Inhibition in
Holz C; Lange S; Sekora A; Knuebel G; Krohn S; Murua Escobar H; Junghanss C; Richter A
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674872
[TBL] [Abstract][Full Text] [Related]
6. 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis.
Jin S; Cojocari D; Purkal JJ; Popovic R; Talaty NN; Xiao Y; Solomon LR; Boghaert ER; Leverson JD; Phillips DC
Clin Cancer Res; 2020 Jul; 26(13):3371-3383. PubMed ID: 32054729
[TBL] [Abstract][Full Text] [Related]
7. Novel Compounds Synergize With Venetoclax to Target KMT2A-Rearranged Pediatric Acute Myeloid Leukemia.
Tregnago C; Benetton M; Da Ros A; Borella G; Longo G; Polato K; Francescato S; Biffi A; Pigazzi M
Front Pharmacol; 2021; 12():820191. PubMed ID: 35153769
[TBL] [Abstract][Full Text] [Related]
8. Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies.
Zhai Y; Tang Q; Fang DD; Deng J; Zhang K; Wang Q; Yin Y; Fu C; Xue SL; Li N; Zhou F; Yang D
Clin Cancer Res; 2023 Jan; 29(1):183-196. PubMed ID: 36240005
[TBL] [Abstract][Full Text] [Related]
9. HMGA2 as a potential molecular target in KMT2A-AFF1-positive infant acute lymphoblastic leukaemia.
Wu Z; Eguchi-Ishimae M; Yagi C; Iwabuki H; Gao W; Tauchi H; Inukai T; Sugita K; Ishii E; Eguchi M
Br J Haematol; 2015 Dec; 171(5):818-29. PubMed ID: 26403224
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of Carfilzomib for Infant
Cheung LC; de Kraa R; Oommen J; Chua GA; Singh S; Hughes AM; Ferrari E; Ford J; Chiu SK; Stam RW; Kees UR; Malinge S; Kotecha RS
Front Oncol; 2021; 11():631594. PubMed ID: 33937032
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
Othman TA; Tenold ME; Moskoff BN; Azenkot T; Jonas BA
Expert Rev Hematol; 2021 May; 14(5):407-417. PubMed ID: 34076549
[TBL] [Abstract][Full Text] [Related]
12. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
[TBL] [Abstract][Full Text] [Related]
13. Cryptic recurrent ACIN1-NUTM1 fusions in non-KMT2A-rearranged infant acute lymphoblastic leukemia.
Pincez T; Landry JR; Roussy M; Jouan L; Bilodeau M; Laramée L; Couture F; Sinnett D; Gendron P; Hébert J; Oligny L; Rouette A; Tran TH; Wilhelm BT; Bittencourt H; Cellot S
Genes Chromosomes Cancer; 2020 Feb; 59(2):125-130. PubMed ID: 31515871
[TBL] [Abstract][Full Text] [Related]
14. Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen.
Ohmoto A; Fuji S
Expert Rev Hematol; 2023; 16(10):761-771. PubMed ID: 37670667
[TBL] [Abstract][Full Text] [Related]
15. Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia.
Khabirova E; Jardine L; Coorens THH; Webb S; Treger TD; Engelbert J; Porter T; Prigmore E; Collord G; Piapi A; Teichmann SA; Inglott S; Williams O; Heidenreich O; Young MD; Straathof K; Bomken S; Bartram J; Haniffa M; Behjati S
Nat Med; 2022 Apr; 28(4):743-751. PubMed ID: 35288693
[TBL] [Abstract][Full Text] [Related]
16. Potent preclinical activity of FLT3-directed chimeric antigen receptor T-cell immunotherapy against
Niswander LM; Graff ZT; Chien CD; Chukinas JA; Meadows CA; Leach LC; Loftus JP; Kohler ME; Tasian SK; Fry TJ
Haematologica; 2023 Feb; 108(2):457-471. PubMed ID: 35950535
[TBL] [Abstract][Full Text] [Related]
17. Single-cell multiomics reveals increased plasticity, resistant populations, and stem-cell-like blasts in KMT2A-rearranged leukemia.
Chen C; Yu W; Alikarami F; Qiu Q; Chen CH; Flournoy J; Gao P; Uzun Y; Fang L; Davenport JW; Hu Y; Zhu Q; Wang K; Libbrecht C; Felmeister A; Rozich I; Ding YY; Hunger SP; Felix CA; Wu H; Brown PA; Guest EM; Barrett DM; Bernt KM; Tan K
Blood; 2022 Apr; 139(14):2198-2211. PubMed ID: 34864916
[TBL] [Abstract][Full Text] [Related]
18. The Bcl-2 inhibitor venetoclax inhibits Nrf2 antioxidant pathway activation induced by hypomethylating agents in AML.
Nguyen LXT; Troadec E; Kalvala A; Kumar B; Hoang DH; Viola D; Zhang B; Nguyen DQ; Aldoss I; Ghoda L; Budde E; Pichiorri F; Rosen S; Forman SJ; Marcucci G; Pullarkat V
J Cell Physiol; 2019 Aug; 234(8):14040-14049. PubMed ID: 30623427
[TBL] [Abstract][Full Text] [Related]
19. Updates in infant acute lymphoblastic leukemia and the potential for targeted therapy.
Kotecha RS
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):611-617. PubMed ID: 36485124
[TBL] [Abstract][Full Text] [Related]
20. [Treatment strategy for infant acute lymphoblastic leukemia].
Miyamura T
Rinsho Ketsueki; 2022; 63(7):791-798. PubMed ID: 35922950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]